Significant Anxiolytic Effect and Enhanced Recovery Benefits of Perioperative Low-Dose Olanzapine in Patients with Anxiety Undergoing THA: A Randomized Controlled Trial.

この研究はインパクトが大きい可能性があると判断されました。 OEのAIによるハイインパクト指標は、論文が掲載されたジャーナルと論文自体の科学的内容の両方からのシグナルを統合することで、論文の影響力を推定します。 最先端の自然言語処理を用いて開発されたOEハイインパクトモデルは、ジャーナルのインパクトファクターのみよりも、研究の将来の引用実績をより正確に予測します。 これにより、臨床的に意義のある研究をより早く認識することができ、読者は将来の診療を形成する可能性が最も高い論文に焦点を当てることができます。

研究概要

135 patients with hip osteoarthritis and clinically important anxiety symptoms undergoing primary total hip arthroplasty (THA) were randomized to receive perioperative low-dose olanzapine (2.5 mg), alprazolam (0.4 mg), or placebo. The primary outcome was anxiety severity, measured using the State-Trait Anxiety Inventory-State (STAI-S). Secondary outcomes included sleep quality assessed using the Pittsburgh Sleep Quality Index (PSQI), pain measured using the visual analogue scale (VAS), opioid consumption, postoperative nausea and vomiting, and hip function assessed using the Harris Hip Score (HHS) and Hip Disability and Osteoarthritis Outcome Score (HOOS). Outcomes were assessed up to 24 weeks postoperatively. Overall, the results of the study revealed that olanzapine significantly reduced early postoperative anxiety, pain, opioid consumption, and nausea and vomiting while improving sleep quality and functional recovery compared with placebo, with greater early anxiolytic benefits than alprazolam. These findings suggested that short-term, low-dose olanzapine could improve perioperative recovery in patients with anxiety undergoing THA.